<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82741">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02028169</url>
  </required_header>
  <id_info>
    <org_study_id>P13-518</org_study_id>
    <nct_id>NCT02028169</nct_id>
  </id_info>
  <brief_title>To Observe the Impacts of Anti-Tumor Necrosis Factor (TNF) Effectiveness on Improvement in Work Place and Household Productivity for Patients With Psoriatic Arthritis</brief_title>
  <acronym>PsA</acronym>
  <official_title>To Observe the Impacts of Anti-TNF's Effectiveness on Improvement in Work Place and Household Productivity for Patients With Psoriatic Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This post marketing observational study (PMOS) is designed to provide the initial data on
      work impairment of Psoriatic Arthritis (PsA) patients in Turkey, as well as changes in work
      impairment, life quality and clinical response during treatment with anti-TNF agents.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the impact of long term treatment of psoriatic arthritis with anti-TNFs on Absenteeism</measure>
    <time_frame>Up to Month 9</time_frame>
    <description>To collect the number of missed working days and the number of working days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of the impact of long term treatment of psoriatic arthritis with anti-TNFs on Presenteeism</measure>
    <time_frame>Up to Month 9</time_frame>
    <description>To collect the number of working days and the total number of working days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of the impact of long term treatment of psoriatic arthritis with anti-TNFs on work productivity</measure>
    <time_frame>Up to Month 9</time_frame>
    <description>To collect overall work impairment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of the impact of long term treatment of psoriatic arthritis with anti-TNFs on total daily activity impairment</measure>
    <time_frame>Up to Month 9</time_frame>
    <description>To collect total daily activity impairment by Work Productivity and Activity Impairment (WPAI) questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To collect Self-reported functional status using Health Assessed Questionnaire (HAQ) questionnaire</measure>
    <time_frame>Up to Month 9</time_frame>
    <description>To evaluate Self-reported functional status (disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the Anti-TNF treatment effectiveness based percentage of patients achieving American College Rheumatology (ACR) 20/ACR50</measure>
    <time_frame>Up to Month 9</time_frame>
    <description>To evaluate the effectiveness of Anti-TNF treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the Anti-TNF treatment effectiveness based percentage of patients achieving ACR 70</measure>
    <time_frame>Up to Month 9</time_frame>
    <description>To evaluate the effectiveness of Anti-TNF treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Disease Activity Score (DAS 28)</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>To evaluate the effectiveness of Anti-TNF treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Maastricht Ankylosing Spondylitis Enthesitis Score</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>To evaluate the effectiveness of Anti-TNF treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in dactylytis</measure>
    <time_frame>Up to Month 9</time_frame>
    <description>To evaluate the effectiveness of Anti-TNF treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of swollen and/or tender joints</measure>
    <time_frame>Up to Month 9</time_frame>
    <description>To evaluate the effectiveness of Anti-TNF treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in levels of rheumatoid factor</measure>
    <time_frame>Up to Month 9</time_frame>
    <description>To evaluate the effectiveness of Anti-TNF treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Erythrocyte Sedimentation Rate (ESR)</measure>
    <time_frame>Up to Month 9</time_frame>
    <description>To evaluate the effectiveness of Anti-TNF treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in C-reactive protein (CRP)</measure>
    <time_frame>Up to Month 9</time_frame>
    <description>To evaluate the effectiveness of Anti-TNF treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Visual Analog Scale (VAS)</measure>
    <time_frame>Up to Month 9</time_frame>
    <description>To collect physician's and patient's global assessment of disease activity and disease related pain and fatigue to evaluate the effectiveness of Anti-TNF treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with serious adverse events</measure>
    <time_frame>Up to Month 9</time_frame>
    <description>To report serious adverse events (SAE) occurring during treatment with anti-TNF agents</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">125</enrollment>
  <condition>Psoriatic Arthritis</condition>
  <condition>Work Productivity</condition>
  <arm_group>
    <arm_group_label>Psoriatic Arthritis patients treated with Anti-TNF</arm_group_label>
    <description>Psoriatic Arthritis patients treated with Anti-TNF</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients from both genders will be included to this non-interventional epidemiological
        study from selected university or state hospital or Ministry of Health of Turkey training
        and research hospitals in Turkey.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: - Actively working, either full-time or part-time

          -  Previous confirmed diagnosis of PsA by a rheumatologist

          -  Patients for whom the physician has initiated PsA treatment with an Anti-TNF in
             accordance with Turkish Ministry of Health regulations and reimbursement criteria

          -  Able to provide authorization to use and disclose their health related information
             Exclusion Criteria: - Patients with a history of an allergic reaction or significant
             sensitivity to anti-TNF agents

          -  Patients with possible follow-up problems during the planned study period or patients
             who may not be compliant to treatment as evaluated by the investigator/treating
             physician

          -  Patients participating in any clinical trial of an experimental drug 30 days prior to
             the first visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahmut Gücük, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 98055</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 98079</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 119219</name>
      <address>
        <city>Antalya</city>
        <zip>07058</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 126114</name>
      <address>
        <city>Edirne</city>
        <zip>22030</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 98056</name>
      <address>
        <city>Elazig</city>
        <zip>23119</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 98059</name>
      <address>
        <city>Eskisehir</city>
        <zip>26480</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 98078</name>
      <address>
        <city>Gaziantep</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 98075</name>
      <address>
        <city>Gorukle, Bursa</city>
        <zip>16059</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 98080</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 98060</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 126113</name>
      <address>
        <city>Samsun</city>
        <zip>55139</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>http://www.rxabbvie.com</url>
  </link>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 6, 2016</lastchanged_date>
  <firstreceived_date>January 3, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Work Productivity</keyword>
  <keyword>Anti-TNFs</keyword>
  <keyword>Psoriatic Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
